<DOC>
	<DOC>NCT02867085</DOC>
	<brief_summary>The prospective BoHemE study is designed to evaluate the correlation between bone marrow function and skeletal health in elderly patients (&gt;= 60 years) with or without pre-existing myelodysplastic syndromes (MDS).</brief_summary>
	<brief_title>Study Investigating the Interactions of Bone and Hematopoiesis in the Elderly</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Inclusion Criteria Group 1 (MDS group): Age ≥60 years With known or suspected MDS (according WHO, ＜20% blast count) Written informed consent Inclusion Criteria Group 2 (control group): Age ≥60 years Undergoing elective knee or hip replacement therapy Normal blood count (defined by Hb ♀ &gt;12 g/dL, ♂ &gt;13 g/dL; ANC &gt;1.8x10^9/L; PLT &gt;100x10^9/L) Written informed consent Exclusion Criteria Group 1 (MDS group) + 2 (control group): Patients that previously underwent bilateral total hip replacement or patients of the control group that were diagnosed with MDS or AML prior to the study will be excluded. In addition, patients with dementia (MMSE score of &lt;24), renal insufficiency with an eGFR &lt;45 mL/min, liver cirrhosis ChildPugh B or C, active infection (HIV, hepatitis B or C, tuberculosis), heart insufficiency NYHA III or IV, severe cardiac valve disease are not eligible for this study. Moreover, participants who are not able to consent will be excluded from the BoHemE study.</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MDS</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
</DOC>